ClinicalTrials.gg
Active, not recruitingNCT05769777ATLANTISUpdated Apr 23, 2026

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Amlitelimab in Dermatitis Atopic, sponsored by Sanofi. Active, not recruiting at 174 sites in 25 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
999
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
3rd of 11
999 · median 589
Started
2023
with 3 others
Phase 2
4 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).

The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD.

The study duration per participant will be up to 284 weeks, including:

  • A screening period of up to 2 to 4 weeks
  • An open label treatment period of up to 268 weeks (approximately 5 years)
  • A post-treatment safety follow-up period of at least 20 weeks after the last dose administration (last IMP administration at Week 264)

The planned number of visits will be 35 visits.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 12 years of age inclusive, at the time of signing the .
  • Participants must have AD as defined by the American Academy of Dermatology Consensus Criteria for 1 year or longer at baseline.
  • Participant must have documented history (within 6 months prior to screening visit), of inadequate response (including inadequate efficacy or medical inadvisability) to topical treatments and/or inadequate response to systemic therapies (within 12 months prior to screening visit).
  • Eczema Area Severity Index (EASI) of 16 or higher at baseline visit/Visit 2.
  • Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit/Visit 2.
  • AD involvement of 10% or more of body surface area (BSA) at baseline visit/Visit 2.
  • Weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) of ≥ 4 at baseline visit/Visit 2.
  • Able and willing to comply with requested study visits and procedures.
  • Body weight must be greater than or equal to 25 kg.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants must not be pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments as per investigator's judgement
  • Known history of or suspected significant current , including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Any or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and completely cured for more than 5 years prior to baseline).
  • History of solid organ or stem cell transplant.
  • Any pre-planned major elective surgery known about at baseline that in the opinion of the investigator would necessitate that IMP be permanently discontinued or require more than three doses to be missed.
  • Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study.
  • Any medical or psychiatric condition which, in the opinion of the Investigator may present an unreasonable risk to the study participants as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments.
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline (1 week in the event of superficial skin infections); and any infection which as per Investigator's opinion precludes the participant's participation in the study.
  • Treatment with live (attenuated) vaccines within 12 weeks prior to baseline; failure to complete non-live immunizations required by local regulation (eg, vaccination for COVID-19) at least 14 days prior to baseline.
  • Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit.
  • Positive for (HIV), or at the screening visit.
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, non-TB mycobacterial infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening.
  • In the Investigator's opinion, any laboratory results from the clinical chemistry, hematology, coagulation, or urinalysis tests at the screening visit.
  • In the Investigator's opinion, any significant abnormality on 12-lead (ECG) at the screening visit that could be suggestive of an unstable or underlying cardio-vascular condition that could preclude the participant's participation in the study.
  • History of or allergy to any of the or IMP or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
999 participants (actual)

Study arms

  • Experimental
    Amlitelimab

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

Interventions

  • Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)

    Percentage of participants who experienced TEAEs from baseline during the study

    Time frame: Baseline up to end of study (EOS) (Week 284)

  2. Percentage of participants who experienced Treatment-Emergent Serious Adverse Events (TESAEs)

    Percentage of participants who experienced TESAEs from baseline during the study

    Time frame: Baseline up to EOS (Week 284)

Secondary outcomes

  1. Percentage of participants who experienced Treatment-Emergent Adverse Events of Special Interest (AESI)

    Percentage of participants who experienced AESI from baseline during the study

    Time frame: Baseline up to EOS (Week 284)

  2. Percentage of participants with Potentially Clinically Significant Abnormalities (PCSA) for vital signs and clinical laboratory assessments, and electrocardiogram (ECG)

    Time frame: Baseline up to EOS (Week 284)

  3. Percentage of participants discontinued from study treatment due to Adverse Events (AEs)

    Time frame: Baseline up to EOS (Week 284)

  4. Percent change from baseline in Eczema Area and Severity Index (EASI) score

    The EASI is an Investigator-assessed tool used to measure the extent (area) and severity of AD. The severity is assessed based on 4 disease characteristics (erythema, induration/papulation, excoriation and lichenification). The extent of involvement of AD is assessed in 4 body regions (head/neck, trunk, upper extremities and lower extremities). Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to EOS (Week 284)

  5. Proportion of participants with at least a 75% reduction from baseline in the EASI (EASI-75)

    Time frame: Baseline to EOS (Week 284)

  6. Proportion of participants with at least a 50% reduction from baseline in the EASI (EASI-50)

    Time frame: Baseline to EOS (Week 284)

  7. Proportion of participants with at least a 90% reduction from baseline in the EASI (EASI-90)

    Time frame: Baseline to EOS (Week 284)

  8. Proportion of participants with at least 100% reduction from baseline in the EASI (EASI-100)

    Time frame: Baseline to EOS (Week 284)

  9. Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction of ≥2 points from baseline

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to EOS (Week 284)

  10. Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) and a reduction from baseline of ≥2 points

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to EOS (Week 284)

  11. Proportion of participants with vIGA-AD of 0

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to EOS (Week 284)

  12. Change in percent Body Surface Area (BSA) affected by AD from baseline

    BSA affected by AD will measure the extent (area) of the disease.

    Time frame: Baseline to EOS (Week 284)

  13. Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline

    The SCORAD Index is a clinical tool used to standardise the evaluation of the extent and severity of AD. To determine the extent of AD, the affected area (A) as a percentage of the whole body is determined, with a maximum score of 100%. The severity (B) of 6 specific symptoms of AD (redness, swelling, oozing/crusting, scratch marks, skin thickening \[lichenification\], dryness \[area where there is no inflammation\]) is assessed on a 4-point scale, with a maximum score of 18: none (0), mild (1), moderate (2) or severe (3). Subjective symptoms (C): itch and sleeplessness are recorded as scored by the participants or relative on a visual analogue scale (VAS), where 0 = no itch (or sleeplessness) and 10 = worst imaginable itch (or sleeplessness), with a maximum possible score of 20.

    Time frame: Baseline to EOS (Week 284)

  14. Proportion of participants requiring rescue treatment at each visit

    Time frame: Baseline to EOS (Week 284)

  15. Proportion of participants with ≥4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS ≥4

    The PP-NRS is a single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours, with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to EOS (Week 284)

  16. Proportion of participants with PP-NRS 0 or 1

    The PP-NRS is a single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours, with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to EOS (Week 284)

  17. Percent change in weekly average of daily PP-NRS from baseline

    The PP-NRS is a single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours, with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to EOS (Week 284)

  18. Change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD during the past 24 hours, with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to EOS (Week 284)

  19. Proportion of participants with a reduction in weekly average of daily SP-NRS ≥4 from baseline in participants with baseline weekly average of daily SP-NRS ≥4

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD during the past 24 hours, with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to EOS (Week 284)

  20. Change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD, with 0 being 'no sleep loss related to the symptoms of atopic dermatitis' and 10 being 'I did not sleep at all' due to the symptoms of atopic dermatitis".

    Time frame: Baseline to EOS (Week 284)

  21. Proportion of participants with a reduction in weekly average of daily SD-NRS ≥3 from baseline in participants with Baseline weekly average of daily SD-NRS ≥3

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD, with 0 being 'no sleep loss related to the symptoms of atopic dermatitis' and 10 being 'I did not sleep at all' due to the symptoms of atopic dermatitis".

    Time frame: Baseline to EOS (Week 284)

  22. Change in Patient Oriented Eczema Measure (POEM) from baseline

    The POEM is a 7-item self-assessment questionnaire used for monitoring atopic eczema severity, focusing on the signs and symptoms as experienced by the patient during the past 7 days. Total score ranges from 0 to 28.

    Time frame: Baseline to EOS (Week 284)

  23. Proportion of participants with a reduction in POEM ≥4 from Baseline in participants with POEM baseline ≥4

    The POEM is a 7-item self-assessment questionnaire used for monitoring atopic eczema severity, focusing on the signs and symptoms as experienced by the patient during the past 7 days. Total score ranges from 0 to 28.

    Time frame: Baseline to EOS (Week 284)

  24. Proportion of adolescent participants with a reduction in POEM ≥6 from Baseline in adolescents with POEM baseline ≥6

    The POEM is a 7-item self-assessment questionnaire used for monitoring atopic eczema severity, focusing on the signs and symptoms as experienced by the patient during the past 7 days. Total score ranges from 0 to 28.

    Time frame: Baseline to EOS (Week 284)

  25. Change in Atopic Dermatitis Control Test (ADCT) from baseline

    The ADCT is a 6-item patient-reported outcomes instrument with a 7-day recall period to measure AD disease control. Total score ranges from 0 to 24.

    Time frame: Baseline to EOS (Week 284)

  26. Proportion of participants with a reduction in ADCT ≥5 from baseline in participants with baseline ADCT≥7

    The ADCT is a 6-item patient-reported outcomes instrument with a 7-day recall period to measure AD disease control. Total score ranges from 0 to 24.

    Time frame: Baseline to EOS (Week 284)

  27. Change in Dermatology Quality of Life Index (DLQI) from baseline in participants with age ≥16 years old

    The DLQI is a 10-item questionnaire to measure dermatology specific quality of life (QoL), covering the participant's previous week (i.e. past 7 days). Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: Baseline to EOS (Week 284)

  28. Change in Children's Dermatology Life Quality Index (CDLQI) from baseline in participants with age ≥12 to <16 years old

    The CDLQI is a 10-item questionnaire to assess the impact of skin disease on a child's health related quality of life (HRQoL) over a recall period of 1 week. It is validated in children aged 4 to \<16 years. Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: Baseline to EOS (Week 284)

  29. Proportion of participants with age ≥12 to <16 with a reduction in CDLQI ≥4 from Baseline in participants with age ≥12 to <16 years old with CDLQI at baseline ≥6

    The CDLQI is a 10-item questionnaire to assess the impact of skin disease on a child's health related quality of life (HRQoL) over a recall period of 1 week. It is validated in children aged 4 to \<16 years. Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: Baseline to EOS (Week 284)

  30. Proportion of participants with age ≥12 to <16 with a reduction in CDLQI ≥6 from Baseline in participants with age ≥12 to <16 years old with CDLQI at baseline ≥6

    The CDLQI is a 10-item questionnaire to assess the impact of skin disease on a child's health related quality of life (HRQoL) over a recall period of 1 week. It is validated in children aged 4 to \<16 years. Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: Baseline to EOS (Week 284)

  31. Proportion of participants with a reduction in DLQI ≥4 from Baseline in participants with age ≥16 years old and with DLQI at baseline ≥4

    The DLQI is a 10-item questionnaire to measure dermatology specific quality of life (QoL), covering the participant's previous week (i.e. past 7 days). Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: Baseline to EOS (Week 284)

  32. Change in Patient Global Impression of Severity (PGIS) from baseline

    The PGIS is a single item tool used to assess current severity of eczema symptoms, scored on a 5-point scale from 1 = no symptoms to 5 = very severe symptoms.

    Time frame: Baseline to EOS (Week 284)

  33. Proportions of participants who report symptoms to be "No" on the PGIS score

    The PGIS is a single item tool used to assess current severity of eczema symptoms, scored on a 5-point scale from 1 = no symptoms to 5 = very severe symptoms.

    Time frame: Baseline to EOS (Week 284)

  34. Proportions of participants who report symptoms to be "No" or "Mild" on the PGIS score

    The PGIS is a single item tool used to assess current severity of eczema symptoms, scored on a 5-point scale from 1 = no symptoms to 5 = very severe symptoms.

    Time frame: Baseline to EOS (Week 284)

  35. Proportion of participants who respond "Much better" on the Patient Global Impression of (PGIC) scale

    The PGIC is a single item global tool used in the assessment of AD, scored on a 5-point scale from 1 = Much improved to 5 = Much worse.

    Time frame: Week 16 to EOS (Week 284)

  36. Proportion of participants who respond "Much better" or "A little better" on the PGIC scale

    The PGIC is a single item global tool used in the assessment of AD, scored on a 5-point scale from 1 = Much improved to 5 = Much worse.

    Time frame: Week 16 to EOS (Week 284)

  37. Proportion of participants by PGIC responses

    The PGIC is a single item global tool used in the assessment of AD, scored on a 5-point scale from 1 = Much improved to 5 = Much worse.

    Time frame: Week 16 to EOS (Week 284)

  38. Change in Hospital Anxiety Depression Scale (HADS) from baseline

    The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression.

    Time frame: Baseline to EOS (Week 284)

  39. Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A ≥8

    The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression. HADS-A is the anxiety HADS subscale.

    Time frame: Baseline to EOS (Week 284)

  40. Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D Baseline ≥8

    The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression. HADS-D is the depression HADS subscale.

    Time frame: Baseline to EOS (Week 284)

07

Study locations

174 sites
  • Allervie Clinical Research - Birmingham- Site Number : 8400050
    Birmingham, Alabama 35209, United States
  • Research Solutions of Arizona- Site Number : 8400020
    Litchfield Park, Arizona 85340, United States
  • Dermatology Trial Associates- Site Number : 8400027
    Bryant, Arkansas 72022, United States
  • University Dermatology Trials- Site Number : 8400052
    Newport Beach, California 92660, United States
  • Children's Hospital Colorado - Aurora- Site Number : 8400041
    Aurora, Colorado 80045, United States
  • IMMUNOe International Research Centers - Centennial- Site Number : 8400024
    Centennial, Colorado 80112, United States
  • Renaissance Research and Medical Group- Site Number : 8400006
    Cape Coral, Florida 33991, United States
  • Florida Pharmaceutical Research and Associates- Site Number : 8400018
    Miami, Florida 33143, United States
  • Miami Clinical Research Tower- Site Number : 8400036
    Miami, Florida 33155, United States
  • Florida Research Center- Site Number : 8400011
    Miami, Florida 33174, United States
  • Clinical Research Trials of Florida- Site Number : 8400054
    Tampa, Florida 33607, United States
  • Advanced Medical Research - Atlanta- Site Number : 8400044
    Atlanta, Georgia 30342, United States
  • Georgia Skin & Cancer Clinic- Site Number : 8400048
    Savannah, Georgia 31419, United States
  • Sneeze Wheeze & Itch Associates- Site Number : 8400002
    Normal, Illinois 61761, United States
  • Kentucky Advanced Medical Research- Site Number : 8400014
    Murray, Kentucky 42071, United States
  • The Derm Institute of West Michigan- Site Number : 8400043
    Caledonia, Michigan 49316, United States
  • Michigan Dermatology Institute - Livonia- Site Number : 8401010
    Livonia, Michigan 48152, United States
  • Michigan Dermatology Institute - Waterford- Site Number : 8400010
    Waterford, Michigan 48328, United States
  • Dermatology Research Center of Oklahoma- Site Number : 8400035
    Tulsa, Oklahoma 74132, United States
  • The Children's Hospital of Philadelphia- Site Number : 8400009
    Philadelphia, Pennsylvania 19104, United States
  • Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400053
    San Antonio, Texas 78218, United States
  • Private Practice - Dr. Marthe N. Dika- Site Number : 8400022
    Burlington, Wisconsin 53105, United States
  • Investigational Site Number : 0320022
    General Pico, La Pampa Province 6360, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320008
    Buenos Aires, 1023, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1181, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1427, Argentina
  • Investigational Site Number : 0360002
    Kogarah, New South Wales 2217, Australia
  • Investigational Site Number : 0360001
    Sydney, New South Wales 2010, Australia
  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760002
    Salvador, Estado de Bahia 41820-020, Brazil
  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022
    Curitiba, Paraná 80060-900, Brazil
  • Pontifica Universidade Catolica do Parana- Site Number : 0760023
    Curitiba, Paraná 80215-901, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760008
    Ribeirão Preto, São Paulo 14049-900, Brazil
  • Faculdade de Medicina do ABC- Site Number : 0760001
    Santo André, São Paulo 09060-650, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760003
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760006
    Sorocaba, São Paulo 18040-425, Brazil
  • IDERJ - Instituto de Dermatologia e Estética do Brasil- Site Number : 0760004
    Rio de Janeiro, 22470-220, Brazil
  • Investigational Site Number : 1240001
    Calgary, Alberta T2G 1B1, Canada
  • Investigational Site Number : 1240051
    Vancouver, British Columbia V6t 2b5, Canada
  • Investigational Site Number : 1240009
    Etobicoke, Ontario M8X 1Y9, Canada
  • Investigational Site Number : 1240008
    Mississauga, Ontario L5H 1G9, Canada
  • Investigational Site Number : 1240011
    Oakville, Ontario L6J 7W5, Canada
  • Investigational Site Number : 1240004
    Peterborough, Ontario K9J 5K2, Canada
  • Investigational Site Number : 1240003
    Richmond Hill, Ontario L4B 1L1, Canada
  • Investigational Site Number : 1240012
    Toronto, Ontario M3H 5Y8, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H3G 2S6, Canada
  • Investigational Site Number : 1240010
    Québec, Quebec G1V 4X7, Canada
  • Investigational Site Number : 1240006
    Québec, Quebec G1W 4R4, Canada
  • Investigational Site Number : 1240044
    Saskatoon, Saskatchewan S7T 0G3, Canada
  • Investigational Site Number : 1520009
    Osorno, Los Lagos Region 5311523, Chile
  • Investigational Site Number : 1520004
    Valdivia, Los Ríos Region 5110683, Chile
  • Investigational Site Number : 1520013
    Lo Barnechea, Reg Metropolitana de Santiago 7691236, Chile
  • Investigational Site Number : 1520011
    Santiago, Reg Metropolitana de Santiago 7500505, Chile
  • Investigational Site Number : 1520008
    Santiago, Reg Metropolitana de Santiago 7500588, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520010
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number : 1520014
    Chillan, 3800761, Chile
  • Investigational Site Number : 1560015
    Beijing, 100045, China
  • Investigational Site Number : 1560008
    Changchun, 130041, China
  • Investigational Site Number : 1560016
    Changsha, 410007, China
  • Investigational Site Number : 1560014
    Chengdu, 610017, China
  • Investigational Site Number : 1560072
    Fuzhou, 350001, China
  • Investigational Site Number : 1560074
    Guangzhou, 510120, China
  • Investigational Site Number : 1560044
    Hangzhou, 310003, China
  • Investigational Site Number : 1560013
    Jingzhou, 434020, China
  • Investigational Site Number : 1560001
    Shanghai, 200040, China
  • Investigational Site Number : 1560018
    Suzhou, 215006, China
  • Investigational Site Number : 1560010
    Taiyuan, 030001, China
  • Investigational Site Number : 1560073
    Taizhou, 318000, China
  • Investigational Site Number : 1560019
    Xinxiang, 453100, China
  • Investigational Site Number : 1560012
    Yinchuan, 750004, China
  • Investigational Site Number : 1560011
    Yiwu, 322000, China
  • Investigational Site Number : 1560028
    Zhenjiang, 212000, China
  • Investigational Site Number : 2032105
    Nový Jičín, 741 01, Czechia
  • Investigational Site Number : 2032104
    Ostrava, 702 00, Czechia
  • Investigational Site Number : 2032102
    Prague, 100 00, Czechia
  • Investigational Site Number : 2030003
    Prague, 100 34, Czechia
  • Investigational Site Number : 2030006
    Prague, 160 00, Czechia
  • Investigational Site Number : 2030007
    Prague, 180 81, Czechia
  • Investigational Site Number : 2080001
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2500004
    Créteil, 94010, France
  • Investigational Site Number : 2500001
    Lille, 59037, France
  • Investigational Site Number : 2500005
    Marseille, 13885, France
  • Investigational Site Number : 2500009
    Nantes, 44093, France
  • Investigational Site Number : 2500003
    Paris, 75010, France
  • Investigational Site Number : 2500006
    Pierre-Bénite, 69495, France
  • Investigational Site Number : 2500002
    Toulouse, 31059, France
  • Investigational Site Number : 2760020
    Augsburg, 86150, Germany
  • Investigational Site Number : 2760009
    Bad Bentheim, 48455, Germany
  • Investigational Site Number : 2762203
    Berlin, 10117, Germany
  • Investigational Site Number : 2762205
    Dresden, 01307, Germany

Showing the first 100 of 174 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2031, 98 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 98 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 15, 2023
StartActual
Apr 3, 2023
Primary completionEst.
Jun 11, 2031
CompletionEst.
Jun 11, 2031
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05769777
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Apr 3, 2023
Primary completion
Jun 11, 2031 (estimated)
Completion
Jun 11, 2031 (estimated)
Last update
Apr 23, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion